ClinicalTrials.gg
CompletedNCT00504777Updated Aug 4, 2014Results posted

A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.

A Phase 4 interventional study of rituximab [MabThera/Rituxan] and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 10 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-04.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
96th of 113
36 · median 130
Started
2007
with 8 others
Phase 4
38 of 113
3 open now
Registered
24th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 96th largest by enrollment, is one of 9 that started in 2007, is one of 38 in phase 4, and was the 24th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single arm study will assess the safety and efficacy of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response or intolerance to one or more anti-TNF agents. Patients will receive MabThera 1000mg i.v. on days 1 and 15, and methotrexate (10-25mg/week p.o. or parenteral), together with methylprednisolone 100mg i.v. prior to infusion of MabThera. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • active rheumatoid arthritis;
  • receiving outpatient treatment;
  • an inadequate response, or intolerance, to >=1 anti-TNF agent.

Exclusion criteria

Exclusion Criteria:

  • other rheumatic disease or inflammatory joint disease;
  • concurrent treatment with any anti-TNF-alpha therapy;
  • joint or osseous surgery during 8 weeks prior to recruitment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan] · Drug: Methotrexate

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000mg iv on days 1 and 15

  • 10-25mg/week po or parenteral

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score Based on 28-Joint Count (DAS28)

    DAS28 was calculated from the number of swollen joints, or swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (measured in millimeters per hour \[mm/hr\]), and Patient Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A clinically significant improvement in DAS28 was a change of at least 1.2 units.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology (ACR) Response

    ACR20/50/70 response defined as greater than or equal to (≥)20 percent (%), 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%/50%/70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain, Patient Global Assessment of Disease Activity, Physician Global Assessment of Disease Activity, self-assessed disability based on the Health Assessment Questionnaire-Disability Index (HAQ-DI), and C-Reactive Protein (CRP).

    Time frame: Week 24

  2. Percentage of Participants Achieving a Response by European League Against Rheumatism (EULAR) Category

    Percentage of participants with a EULAR response at Week 24 based on a scale of good response, moderate response, or no response. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders have a change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders have a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders have a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.

    Time frame: Week 24

  3. Change From Baseline in HAQ-DI Score

    The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set are scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person is required. The HAQ-DI score is calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".

    Time frame: Week 24

07

Results

Posted Aug 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab + Methotrexate (MTX)
Started36
Completed35
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange From Baseline in Disease Activity Score Based on 28-Joint Count (DAS28)

DAS28 was calculated from the number of swollen joints, or swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (measured in millimeters per hour \[mm/hr\]), and Patient Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A clinically significant improvement in DAS28 was a change of at least 1.2 units.

Time frame:
Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in Disease Activity Score Based on 28-Joint Count (DAS28)
scores on a scaleRituximab + MTX
Baseline5.51 ± 1.05
Week 244.39 ± 1.21
Change from Baseline to Week 24-1.12 ± 1.19
Statistical analysis
  • Rituximab + MTX · t-test, 2 sided · p = <0.0001
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) Response

ACR20/50/70 response defined as greater than or equal to (≥)20 percent (%), 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%/50%/70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain, Patient Global Assessment of Disease Activity, Physician Global Assessment of Disease Activity, self-assessed disability based on the Health Assessment Questionnaire-Disability Index (HAQ-DI), and C-Reactive Protein (CRP).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) Response
percentage of participantsRituximab + MTX
ACR202.78
ACR500
ACR700
SecondaryPercentage of Participants Achieving a Response by European League Against Rheumatism (EULAR) Category

Percentage of participants with a EULAR response at Week 24 based on a scale of good response, moderate response, or no response. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders have a change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders have a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders have a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response by European League Against Rheumatism (EULAR) Category
percentage of participantsRituximab + MTX
Good response0
Moderate response58.33
No response41.67
SecondaryChange From Baseline in HAQ-DI Score

The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set are scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person is required. The HAQ-DI score is calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".

Time frame:
Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in HAQ-DI Score
scores on a scaleRituximab + MTX
Baseline1.07 ± 0.69
Week 240.81 ± 0.65
Change from Baseline to Week 24-0.26 ± 0.52
Statistical analysis
  • Rituximab + MTX · t-test, 2 sided · p = 0.0054

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + MTX—3/36 (8.3%)22/36 (61.1%)
Most frequent serious events
Most frequent serious events
EventRituximab + MTX
Spinal column stenosisMusculoskeletal and connective tissue disorders1/36
CholelithiasisHepatobiliary disorders1/36
Back painMusculoskeletal and connective tissue disorders1/36
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRituximab + MTX
Upper respiratory tract infectionInfections and infestations8/36
CoughRespiratory, thoracic and mediastinal disorders5/36
DizzinessCardiac disorders2/36
FatigueGeneral disorders2/36
NasopharyngitisRespiratory, thoracic and mediastinal disorders2/36
RashSkin and subcutaneous tissue disorders2/36
HypertensionVascular disorders2/36
LeukocytosisBlood and lymphatic system disorders1/36
Mononucleosis syndromeBlood and lymphatic system disorders1/36
Abdominal pain upperGastrointestinal disorders1/36

Baseline characteristics

Intent-to-Treat (ITT) Population: all participants who recieved any part of an infusion.

Age, Continuous
Age, Continuous(years)Rituximab + MTX
Mean50.72 ± 13.42
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + MTX
Female33
Male3
08

Study locations

10 sites
  • Changhua, 500, Taiwan
  • Kaohsiung, 00833, Taiwan
  • Kaohsiung, 807, Taiwan
  • Kaohsiung, 813, Taiwan
  • Taichung, 402, Taiwan
  • Taichung, 404, Taiwan
  • Taichung, 407, Taiwan
  • Taipei, 00112, Taiwan
  • Taoyuan, 333, Taiwan
  • Tapei, 114, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2007
First posted
Jul 20, 2007
Start
Jul 2007
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Aug 4, 2014
Last update
Aug 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00504777
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 20, 2007
Start date
Jul 2007
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Aug 4, 2014
Last update
Aug 4, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion